Search Results - "Ejlertsen, B."

Late toxicity of breast cancer treatment and bone health by Ejlertsen, B.

Get full text

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel by Hadji, P., Coleman, R.E., Wilson, C., Powles, T.J., Clézardin, P., Aapro, M., Costa, L., Body, J.-J., Markopoulos, C., Santini, D., Diel, I., Di Leo, A., Cameron, D., Dodwell, D., Smith, I., Gnant, M., Gray, R., Harbeck, N., Thurlimann, B., Untch, M., Cortes, J., Martin, M., Albert, U.-S., Conte, P.-F., Ejlertsen, B., Bergh, J., Kaufmann, M., Holen, I.

“…Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their ability to prevent cancer treatment-induced bone loss…”
Get full text

Rates of re‐excision and conversion to mastectomy after breast‐conserving surgery with or without oncoplastic surgery: a nationwide population‐based study by Heeg, E., Jensen, M. B., Hölmich, L. R., Bodilsen, A., Tollenaar, R. A. E. M., Lænkholm, A. V., Offersen, B. V., Ejlertsen, B., Mureau, M. A. M., Christiansen, P. M.

“…Background There is no consensus regarding the impact of oncoplastic surgery (OPS) on rates of re‐excision and conversion to mastectomy following…”
Get full text

Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer by Eckhoff, L., Knoop, A. S., Jensen, M.-B., Ejlertsen, B., Ewertz, M.

“…Docetaxel-induced peripheral neuropathy (PN) can lead to sub-optimal treatment in women with early breast cancer. Here, we compare the frequency of dose…”
Get full text

Opioids and breast cancer recurrence: A Danish population‐based cohort study by Cronin‐Fenton, Deirdre P., Heide‐Jørgensen, Uffe, Ahern, Thomas P., Lash, Timothy L., Christiansen, Peer M., Ejlertsen, Bent, Sjøgren, Per, Kehlet, Henrik, Sørensen, Henrik T.

“…BACKGROUND Opioids may alter immune function, thereby potentially affecting cancer recurrence. The authors investigated the association between postdiagnosis…”
Get full text

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 by Curigliano, G, Burstein, H J, Winer, E P, Gnant, M, Dubsky, P, Loibl, S, Colleoni, M, Regan, M M, Piccart-Gebhart, M, Senn, H -J, Thürlimann, B, André, F, Baselga, J, Bergh, J, Bonnefoi, H, Brucker, S Y, Cardoso, F, Carey, L, Ciruelos, E, Cuzick, J, Denkert, C, Di Leo, A, Ejlertsen, B, Francis, P, Galimberti, V, Garber, J, Gulluoglu, B, Goodwin, P, Harbeck, N, Hayes, D F, Huang, C -S, Huober, J, Khaled, H, Jassem, J, Jiang, Z, Karlsson, P, Morrow, M, Orecchia, R, Osborne, K C, Pagani, O, Partridge, A H, Pritchard, K, Ro, J, Rutgers, E J T, Sedlmayer, F, Semiglazov, V, Shao, Z, Smith, I, Toi, M, Tutt, A, Viale, G, Watanabe, T, Whelan, T J, Xu, B

Get full text

Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the Netherlands by Heeg, E., Jensen, M. B., Mureau, M. A. M., Ejlertsen, B., Tollenaar, R. A. E. M., Christiansen, P. M., Vrancken Peeters, M. T. F. D.

“…Purpose Breast-contour preservation (BCP) is possible for most women treated for early-stage breast cancer. BCP can be defined as primary breast-conserving…”
Get full text

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial by Delaloge, S., Cella, D., Ye, Y., Buyse, M., Chan, A., Barrios, C.H., Holmes, F.A., Mansi, J., Iwata, H., Ejlertsen, B., Moy, B., Chia, S.K.L., Gnant, M., Smichkoska, S., Ciceniene, A., Martinez, N., Filipović, S., Ben-Baruch, N.E., Joy, A.A., Langkjer, S.T., Senecal, F., de Boer, R.H., Moran, S., Yao, B., Bryce, R., Auerbach, A., Fallowfield, L., Martin, M.

“…We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET…”
Get full text

Symptoms of endocrine treatment and outcome in the BIG 1-98 study by Huober, J., Cole, B. F., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B.

“…There may be a relationship between the incidence of vasomotor and arthralgia/myalgia symptoms and treatment outcomes for postmenopausal breast cancer patients…”
Get full text

Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study by Jensen, M.-B., Pedersen, C. B., Misiakou, M.-A., Talman, M.-L. M., Gibson, L., Tange, U. B., Kledal, H., Vejborg, I., Kroman, N., Nielsen, F. C., Ejlertsen, B., Rossing, M.

“…Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast…”
Get full text

Exercise despite pain - breast cancer patient experiences of muscle and joint pain during adjuvant chemotherapy and concurrent participation in an exercise intervention by Andersen, C., Rørth, M., Ejlertsen, B., Adamsen, L.

“…Chemotherapy‐related pain is a well‐known side effect in cancer patient receiving chemotherapy. However, limited knowledge exists describing whether exercise…”
Get full text

A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1) by Lindman, H., Andersson, M., Ahlgren, J., Balslev, E., Sverrisdottir, A., Holmberg, S.B., Bengtsson, N.O., Jacobsen, E.H., Jensen, A.B., Hansen, J., Tuxen, M.K., Malmberg, L., Villman, K., Anderson, H., Ejlertsen, B., Bergh, J., Blomqvist, C.

“…Retrospective studies have demonstrated a worse outcome in breast cancer patients not developing leukopenia during adjuvant chemotherapy. The SBG 2000-1 is the…”
Get full text

1814 Vaginal estrogens and risk of recurrence or death in women treated for estrogen receptor positive breast cancer by Cold, S, Cold, F, Jensen, M.-B, Christiansen, P, Ejlertsen, B

Get full text

Corrections to “De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017” by Curigliano, G., Burstein, H.J., P. Winer, E., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M.M., Piccart-Gebhart, M., Senn, H.-J., Thürlimann, B., André, F., Baselga, J., Bergh, J., Bonnefoi, H., Y. Brucker, S., Cardoso, F., Carey, L., Ciruelos, E., Cuzick, J., Denkert, C., Di Leo, A., Ejlertsen, B., Francis, P., Galimberti, V., Garber, J., Gulluoglu, B., Goodwin, P., Harbeck, N., Hayes, D.F., Huang, C.-S., Huober, J., Khaled, H., Jassem, J., Jiang, Z., Karlsson, P., Morrow, M., Orecchia, R., Osborne, K.C., Pagani, O., Partridge, A.H., Pritchard, K., Ro, J., Rutgers, E.J.T., Sedlmayer, F., Semiglazov, V., Shao, Z., Smith, I., Toi, M., Tutt, A., Viale, G., Watanabe, T., Whelan, T.J., Xu, B.

Get full text

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial by Munzone, E., Giobbie-Hurder, A., Gusterson, B.A., Mallon, E., Viale, G., Thürlimann, B., Ejlertsen, B., MacGrogan, G., Bibeau, F., Lelkaitis, G., Price, K.N., Gelber, R.D., Coates, A.S., Goldhirsch, A., Colleoni, M.

“…We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or…”
Get full text

Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al by Dubsky, P., Curigliano, G., Burstein, H.J., Winer, E.P., Gnant, M., Loibl, S., Colleoni, M., Regan, M.M., Piccart-Gebhart, M., Senn, H.-J., Thürlimann, B., André, F., Baselga, J., Bergh, J., Bonnefoi, H., Brucker, S.Y., Cardoso, F., Carey, L., Ciruelos, E., Cuzick, J., Denkert, C., Di Leo, A., Ejlertsen, B., Francis, P., Galimberti, V., Garber, J., Gulluoglu, B., Goodwin, P., Harbeck, N., Hayes, D.F., Huang, C.-S., Huober, J., Khaled, H., Jassem, J., Jiang, Z., Karlsson, P., Morrow, M., Orecchia, R., Osborne, K.C., Pagani, O., Partridge, A.H., Pritchard, K., Ro, J., Rutgers, E.J.T., Sedlmayer, F., Semiglazov, V., Shao, Z., Smith, I., Toi, M., Tutt, A., Viale, G., Watanabe, T., Whelan, T.J., Xu, B.

Get full text

16 Prognostic Significance of Axillary Lymph Node Dissection in Breast Cancer Patients with Micrometastases or Isolated Tumor Cells in Sentinel Nodes – a Nationwide Study by Tvedskov, T, Jensen, M, Ejlertsen, B, Balslev, E, Kroman, N

Get full text

SA 8.2 - Late toxicity of breast cancer treatment and bone health by Ejlertsen, B.

Get full text

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial by Ejlertsen, B., Aldridge, J., Nielsen, K.V., Regan, M.M., Henriksen, K.L., Lykkesfeldt, A.E., Müller, S., Gelber, R.D., Price, K.N., Rasmussen, B.B., Viale, G., Mouridsen, H.

“…Estrogen Receptor 1 (ESR1) aberrations may be associated with expression of estrogen receptor (ER) or progesterone receptor (PgR), human epidermal growth…”
Get full text

Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer by Ejlertsen, Bent, Mouridsen, Henning T, Jensen, Maj-Britt, Andersen, Jørn, Cold, Søren, Edlund, Per, Ewertz, Marianne, Jensen, Brita B, Kamby, Claus, Nordenskjold, Bo, Bergh, Jonas

“…Abstract We compared the efficacy of CEF (cyclophosphamide, epirubicin, and fluorouracil) against CMF (cyclophosphamide, methotrexate, and fluorouracil) in…”
Get full text